Triple Agonists (GLP-1/GIP/Glucagon) Class Overview Monograph At a glance Prototype agent / retatrutide (LY3437943), Eli Lilly Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor co-agonism Phase 2 peak weight loss / up to 24.2% body weight at 48 weeks (retatrutide 12 mg) Primary indications in development / obesity, type 2 diabetes, MASLD/MASH, dyslipidemia Route and frequency / once-weekly subcutaneous injection Key differentiator from dual agonists / added glucagon receptor activity drives hepatic fat mobilization and energy expenditure Most common adverse effects / nausea, vomiting, diarrhea, constipation (dose-dependent) Regulatory status (as of mid-2025) / phase 3 trials ongoing
Since CYP3A4 is involved in the metabolism of many drugs, it is likely that high doses of vitamin E would affect the metabolism of a large number of drugs (Ungurianu et al., 2021)
However, when glutathione is depleted by a viral infection like COVID-19 or by environmental toxins like mold mycotoxins, the mast cells lose this protective shield
Be cautious of any source claiming to sell cagrilintidethese products are unregulated and potentially dangerous
Dietary L-carnitine can increase fatty acid -oxidation in mammals, but has produced contradictory results in different fish species
Can semaglutide cause thyroid problems or worsen my existing thyroid condition